ZeroStack to sell Phatebo GmbH to New Horizon Pharma for €2.15M; closing needs German FDI clearance

ZeroStack Corp.

ZeroStack Corp. (formerly Flora Growth Corp.) agreed to sell 100% of German pharma wholesaler Phatebo GmbH to New Horizon Pharma B.V. for €2,150,000 in a locked-box deal struck at Dec 31, 2025.
Of the price, €152,709.44 repays a Phatebo loan; the seller-account balance converts to $2,240,161.09 at the ECB's Nov 2, 2026 rate of 1.1216 USD/EUR.
Phatebo holds a §52a AMG wholesale license, supplies comparators and ancillary drugs for clinical trials, and lists Thermo Fisher Scientific among its key customer contracts.
Closing requires German foreign-investment (AWV/BMWE) clearance; long-stop date is June 30, 2027, extendable to Dec 31, 2027 if BMWE opens a review proceeding.
HRV Global Life Sciences Private Limited, indirect sole shareholder of buyer New Horizon Pharma, issued a non-binding term sheet on Sept 24, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.